1. Home
  2. RYTM vs OLED Comparison

RYTM vs OLED Comparison

Compare RYTM & OLED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • OLED
  • Stock Information
  • Founded
  • RYTM 2008
  • OLED 1985
  • Country
  • RYTM United States
  • OLED United States
  • Employees
  • RYTM N/A
  • OLED N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • OLED Semiconductors
  • Sector
  • RYTM Health Care
  • OLED Technology
  • Exchange
  • RYTM Nasdaq
  • OLED Nasdaq
  • Market Cap
  • RYTM 6.4B
  • OLED 7.1B
  • IPO Year
  • RYTM 2017
  • OLED 1992
  • Fundamental
  • Price
  • RYTM $110.20
  • OLED $148.96
  • Analyst Decision
  • RYTM Strong Buy
  • OLED Strong Buy
  • Analyst Count
  • RYTM 13
  • OLED 7
  • Target Price
  • RYTM $110.38
  • OLED $190.43
  • AVG Volume (30 Days)
  • RYTM 589.3K
  • OLED 544.6K
  • Earning Date
  • RYTM 11-04-2025
  • OLED 11-06-2025
  • Dividend Yield
  • RYTM N/A
  • OLED 1.21%
  • EPS Growth
  • RYTM N/A
  • OLED 9.88
  • EPS
  • RYTM N/A
  • OLED 5.12
  • Revenue
  • RYTM $156,287,000.00
  • OLED $661,991,000.00
  • Revenue This Year
  • RYTM $46.14
  • OLED $6.29
  • Revenue Next Year
  • RYTM $63.37
  • OLED $10.63
  • P/E Ratio
  • RYTM N/A
  • OLED $29.10
  • Revenue Growth
  • RYTM 53.55
  • OLED 6.23
  • 52 Week Low
  • RYTM $45.91
  • OLED $103.70
  • 52 Week High
  • RYTM $113.91
  • OLED $214.57
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 69.35
  • OLED 55.98
  • Support Level
  • RYTM $97.97
  • OLED $139.09
  • Resistance Level
  • RYTM $113.91
  • OLED $150.08
  • Average True Range (ATR)
  • RYTM 3.77
  • OLED 4.96
  • MACD
  • RYTM 1.20
  • OLED 0.51
  • Stochastic Oscillator
  • RYTM 79.43
  • OLED 90.68

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About OLED Universal Display Corporation

Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. The Company has one reportable business segment being OLED technologies and materials. A large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.

Share on Social Networks: